Clinical features and risk factors for interstitial lung disease spreading in low-dose irradiated areas after definitive radiotherapy with or without durvalumab consolidation therapy for patients with non-small cell lung cancer

Table 2 Clinical factors for severity and distribution pattern of interstitial lung disease

		Grade 0–1 ILD	≧Grade 2 ILD	p value	Type I	Type II	p value
		(n = 55)	(n = 19)		(n = 62)	(n = 12)
Age (years)		68	71	0.622	68.5	71	0.597
Sex, n	Male	36	15		41	10
	Female	19	4	0.273	21	2	0.204
Brinkman index		820	990	0.637	783	1000	0.27
Pulmonary fibrosis score, n	0–1	54	15		58	11
	≥ 2	1	4	0.014	4	1	0.598
Pulmonary emphysema score		1	0	0.894	1	0	0.794
LDH (U/L)		197	233	0.015	198	226	0.016
CRP (mg/dL)		0.23	1.05	0.017	0.245	1.05	0.105
HbA1c (%)		5.9	6.1	0.29	5.85	6.9	0.002
Glucose (mg/dL)		102	106	0.26	102	131.5	0.02
KL-6 (U/mL)		324	313	0.821	295	439	0.312
Clinical stage of lung cancer		IIIB	IIIB	0.599	IIIB	IIIB	0.654
Chemotherapy, n	–	16	2		15	3
	+	39	17	0.09	47	9	0.604
Durvalumab, n	–	38	13		44	7
	+	17	6	0.957	18	5	0.293
V ₂₀ (%)		20.8	30.2	0.002	21.2	28.2	0.086
V ₅ (%)		35.6	46.5	0.01	35.9	41.4	0.356
MLD (Gy)		11.6	15.2	0.005	12.1	15	0.21
Vs5 (cc)		2224	1560	0.083	2089	2052	0.912
Lung volume (cc)		3389	3238	0.376	3371	3418	0.907
ILD onset timing (days)		93	61	0.007	93	39	0.001